Panavir injection 5ml ampoules 0.004% 2 pieces

Description

Composition
Active substance:
1 ampoule / vial contains: panavir® (polysaccharides shoots Solanum tuberosum) – 200 micrograms.
Excipients:
Sodium chloride – 0.045 g Water for injection – up to 5 ml.
Description:
Clear or slightly opalescent, colorless or light-brown shade and odorless liquid.
Product form:
A solution for intravenous administration of 0.04 mg / ml.
5 ml ampoules or vials of neutral glass capacity of 5 ml, sealed with rubber stoppers with aluminum caps burnishing.
2 or 5 ampoules in blisters, 1 contour cellular packaging 2 or 5 ampoules, 2 blisters 5 vials together with instructions for use and ampulnam knife or lancet in the stack of cardboard.
When packed in ampoules applying color point and the notch or kink colored rings on the vial, scarifier or ampoule opener can not be embedded.
2 or 5 bottles in blisters, for the contour blister 1 to 2 or 5 vials, 2 blisters 5 vials together with instructions for use in a stack of cardboard.
Contraindications
Idiosyncrasy. Panavir® patients should not be used in case of allergy to composite drug components: glucose, mannose, rhamnose, arabinose, xylose.
Lactation.
Children up to age 12 years.
Dosage
0.04 mg / ml
Indications
Herpesvirus infections of different localization (including recurrent genital herpes, herpes zoster and ophthalmoherpes).
Secondary immunodeficiency state against infectious diseases.
Cytomegalovirus infection, including patients with recurrent miscarriage.
It is used in women with chronic viral infection and interferonodefitsitnym state in preparation for pregnancy.
Chronic cytomegalovirus infection in the acute stage of pregnant women in II and III trimester in the complex therapy.
Human papillomavirus infection (anogenital warts) in the complex therapy.
Gastric ulcer and duodenal ulcer in patients with long-term scarring ulcers and symptomatic gastroduodenal ulcers in the complex therapy.
Tick-borne encephalitis in order to reduce viral load and removal of neurological symptoms (anizorefleksii, reduce reflections, pain exit points of cranial nerves, nystagmus) in a complex therapy.
Rheumatoid arthritis, combining with herpes viral infection in immunocompromised patients (for enhancing the analgesic and anti-inflammatory effect primary therapy), in combined therapy.
SARS and influenza in the complex therapy.
Panavir® used in the treatment of chronic bacterial prostatitis.
Interaction with other drugs
Not registered.
Overdose
Cases of overdose are not logged in. Preclinical studies indicate low toxicity.
pharmachologic effect
Pharmacological group:
Antiviral and immunomodulatory agent.
Pharmacodynamics:
Panavir® – a purified extract of the plant shoots Solanum tuberosum; the main active substance – hexose glycoside consisting of glucose, rhamnose, arabinose, mannose, xylose, galactose, uronic acids.
Panavir® drug is an antiviral and immunomodulatory agent. Increases nonspecific resistance to infections and promotes the induction of interferons alpha and gamma blood leukocytes.
formulation was well tolerated in therapeutic doses.
Tests showed no mutagenic, teratogenic, carcinogenic, allergenic and embryotoxic action. In preclinical studies in laboratory animals, adverse effects on reproduction and fetal development has not been established.
It has anti-inflammatory properties in animal models of edema, exudative, chronic inflammatory proliferative and inflammatory reaction assay pseudoallergic concanavalin A.
Shown analgesic action in models of neuropathic pain and pain caused by inflammation and thermal stimulation.
It possesses antipyretic activity.
In the model parkinsonian syndrome induced by systemic administration of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, shown neuroprotective properties.
It has the ability to improve the function of the retina and optic nerve.
It has wound-healing properties in a gastric ulcer model.
Pharmacokinetics:
When administered intravenously, polysaccharides found in the blood in 5 minutes after the administration, the captured cells of the reticuloendothelial system of the liver and spleen. Withdrawal begins quickly, within 20-30 minutes polysaccharides found in the urine and exhaled air.
Pregnancy and breast-feeding
The use is possible in II and III trimester as indicated by chronic cytomegalovirus infection in the acute stage in the complex therapy. In other cases the use is possible only if the expected benefit to the mother outweighs the potential risk to the fetus. If necessary, use during lactation breastfeeding during the drug should be stopped.
Conditions of supply of pharmacies
Prescription.
side effects
The drug was well tolerated, complications may be associated with individual intolerance and enhanced sensitivity to the constituents of the preparation.
However, the appearance of any adverse side effects need to stop administering the drug and to consult with a physician.
If you notice any other side effects not mentioned in the instructions, tell your doctor.
special instructions
When used in preparation for pregnancy thereby reducing the frequency of reproductive losses cytomegalovirus and herpes virus infections.
When the drug solution turbidity is considered unfit for use.
Effects on ability to drive a vehicle, the mechanism
Data on the possible negative impact of the drug on the ability to drive vehicles and the implementation of potentially hazardous activities that require attention and psychomotor speed reactions, no.
Storage conditions
In the dark place at a temperature of from 2 to 25 ° C. Keep out of the reach of children.
Dosing and Administration
Panavir® be administered intravenously slowly.
The therapeutic dose is 200 mg active substance (the contents of one ampule or vial).
For treatment of herpesvirus infections and tick-borne encephalitis is used twice with an interval of 48 or 24 hours. If necessary, treatment can be repeated after one month.
For the treatment of cytomegalovirus infection and papillomavirus trisubstituted used during the first week at intervals of 48 hours, and twice during the second week at intervals of 72 hours.
For chronic treatment of cytomegalovirus infection in the acute stage pregnant during II and III trimester trisubstituted used during the first week at intervals of 48 hours, and twice during the second week at intervals of 72 hours.
For treatment of gastric ulcer and duodenal ulcer exacerbation and symptomatic gastroduodenal ulcers apply 5 intravenous injections every other day for 10 days.
For the treatment of rheumatoid arthritis, combined with a herpes viral infection in immunocompromised patients applied 5 intravenous injections with an interval of 24-48 hours, if necessary repeat the course after 2 months.
For the treatment of SARS and influenza use two intravenous injections at intervals of 18-24 hours.
For the treatment of patients with chronic bacterial prostatitis are used 5 intravenous injections every 48 hours.
USE IN PEDIATRICS
Panavir® administered to children 12 years of age at a dose of 100 mg intravenously 1 times a day.
For treatment of herpesvirus infections and tick-borne encephalitis is used twice with an interval of 48 or 24 hours. If necessary, after 1 month of treatment can be repeated.
For the treatment of cytomegalovirus infection and papillomavirus trisubstituted used during the first week at intervals of 48 hours, and twice during the second week at intervals of 72 hours.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist